[Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
This review addresses molecular targeted therapies for metastatic breast cancer. As the complex cellular aberrations inherent to cancer cells continue to be revealed, new therapies to target specific cellular pathways are being developed, and several are currently in clinical trials. The most promising of these new agents are discussed focusing on monoclonal antibodies and tyrosine kinase inhibitors to human epidermal growth factor receptors (HER) and vascular endothelial growth factor (VEGF).